“…10,23,54 Orally administered agents have a significantly elevated risk for adverse effects. 6,22,31,56 However, DPN pain is poorly responsive to centrally acting neuropathic pain medications in 60% of patients, leading to chronic opioid use. Despite evidence-based guidelines, opioids remain the most frequently prescribed first-line pain medication; 74% of neuropathy patients receive opioids, but only 35% are eligible with the guidelines.…”